SteriPack Announces Buyout by Inflexion

SteriPack Group (“SteriPack”), a leading global contract manufacturer serving the medical device, pharmaceutical, and diagnostic markets, announces Inflexion Private Equity Partners, a leading UK-based private equity firm, has led the buyout of SteriPack. This strategic partnership positions SteriPack for accelerated growth, geographical expansion, and an enhanced service offering to better support current and future customers.

The funding from Inflexion will support the business to continue to scale globally as it benefits from strong market growth and further international expansion opportunities. SteriPack is also well placed to undertake further acquisitions with the support of Inflexion.

SteriPack provides holistic and integrated product life-cycle management services commencing with award winning product design & development, human factors research & engineering, regulatory, QA, DFM, manufacturing, sterilization, and supply chain management. The company employs over 650 people from its locations in Ireland, Poland, Malaysia, and the US, and has over 100 clients.

Andrew McLean, CEO of SteriPack, said, “We’re very proud of our strong growth record and are keen to build on it to take SteriPack even further as we become even more valued partners to our customers through expansion of our capabilities and geographic footprint. Inflexion’s presence in our core markets of Europe, Asia and the US as well as its extensive M&A experience make it the ideal partner to support our future international growth.”

Florencia Kassai, Partner and Head of Inflexion’s Buyout Fund, commented, “SteriPack is clearly an extremely successful niche market player whose ongoing focus on high-quality innovation has earned it an impressive and loyal client roster. We are incredibly excited to bring our experience to bear to help management accelerate its growth further across the globe.”

SourceSteriPack

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version